BridgeBio Pharma, Inc, trading under the symbol BBIO, is a biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for genetic diseases. Founded in 2015, the company is based in Palo Alto, California, and operates worldwide.
With the genetic diseases being the company's core focus, BridgeBio mainly targets specific mutations in a patient that can cause or significantly contribute to a particular disease. They strive to create therapies by identifying the genetically-driven conditions' right target and develop the best possible delivery methodology.
BridgeBio’s approach is patient-oriented — listening to patients, their families, and their physicians, studying the disease's natural history, and comprehending the genetic science that leads to disease manifestations. The combination of scientific, clinical, and commercial expertise helps the company understand, confront, and potentially change the course of terrible diseases.
To translate scientific discoveries to the clinic rapidly, BridgeBio has built a unique portfolio of product candidates which include more than 30 development programs ranging from early discovery to late-stage development. Notably, the company's therapies in dermatology, cardiology, neurology, endocrinology, renal disease, and ophthalmology are substantially advancing in clinical trials.
The company follows a novel business model where each product candidate is developed by a separate subsidiary. This innovative model aids in focusing the energy and expertise on each separate program while keeping resource allocation efficient and execution-focused.
BridgeBio's mission is written in its name: it serves as a bridge from the discovery of genetic diseases to a future where the diseases are treatable. Their ultimate goal being, transforming the lives of patients who currently have little to no therapeutic options.
The journey to bring impactful medicines to patients is a long and challenging one. But with an excellent leadership team, comprising biotech industry veterans and successful entrepreneurs, and the dedication to scientific innovation, BridgeBio is committed to the advancement of genetic medicines. By pursuing a wide variety of genetic diseases with substantial unmet medical needs and by tirelessly working to develop pioneering treatments, BridgeBio Pharma is making a significant impact in the pharmaceutical industry as well as in the lives of those who need it most.